We have shown that single nucleotide polymorphisms (SNPs) in microRNA (miRNA) genes, miRNA target genes, and miRNA biogenesis genes minimally contribute to colon cancer risk. It is possible that these SNPs alter survival. We analyzed 565 SNPs in or adjacent to microRNAs, target genes, or biogenesis genes, using 1,115 cases and 1,173 controls; 837 cases had survival information. We tested SNPs for associations with colorectal cancer (CRC) survival using a Cox proportional hazard model adjusting for age, study center, gender, AJCC disease stage, and MSI tumor status. Multiple comparison adjustments were made using the step-down Bonferroni correction. SNPs associated with survival (P raw < 0.05) also were assessed with messenger RNA (mRNA). Seven of the 565 SNPs analyzed were associated significantly with CRC survival after adjustment for multiple comparisons. Six of these increased risk of dying, and one, rs12140 (ADAMTS1) decreased risk of dying from CRC (HRR 5 0.44, 95% CI (0.24, 0.83; P Holm 5 0.011). Six SNPs altered colon cancer risk and five were associated with altered mRNA expression across genotypes. One SNP, rs2059691 (PRKRA), was associated with increased mRNA expression and worse survival, and one SNP, rs6598964 (LIN28A), decreased risk of developing colon cancer [OR 5 0.77 95% CI (0.61, 0.98)] and increased risk of dying from CRC (HRR 5 2.26 95% CI (1.52, 3.36). P Holm 5 0.003). The few SNPs associated with CRC survival, colon cancer risk, or with mRNA expression, resided in genes that influence metastasis and angiogenesis.
INTRODUCTION
MiRNAs are endogenous, single-stranded RNA molecules, approximately 22 nucleotides long that bind to mRNA to repress mRNA translation into protein, or degrade the mRNA molecule (Ambros, 2004; Macfarlane and Murphy, 2010; Murray et al., 2010; Arora et al., 2013) . It is generally thought that miRNAs regulate mRNAs via the seed regionnucleotides 2-6 on the 5 0 end of the miRNAbinding the 3 0 UTR of the mRNA (Barrett et al., 2012) . As a single miRNA is able to bind to multiple mRNAs, which in turn participate in a variety of biological responses, miRNAs have been implicated as key effector molecules in cancer development and progression (Baskerville and Bartel, 2005; Lagana et al., 2009; Macfarlane and Murphy, 2010) .
MiRNAs undergo three major processing steps to generate the mature miRNA, and this process involves, directly and indirectly, dozens of proteins (Winter et al., 2009; Krol et al., 2010; Ha and Kim, 2014) . Additionally, single nucleotide polymorphisms (SNPs) within miRNA gene regions may alter miRNA transcription and SNPs within miRNA-targets may influence binding of the miRNA to a target, leaving the miRNA unbound within the cytoplasm and vulnerable to degrading nucleases (Krol et al., 2010) . SNPs within miRNAs, miRNA-biogenesis genes, or in the 3 0 UTR of mRNA targets may alter mature miRNA levels by altering miRNA transcription, mRNA translation, or binding to miRNA target genes (Saunders et al., 2007) ; as such, it has been previously proposed that SNPs in these regions that have been found associated with colon cancer might be operating through altered levels of miRNA expression.
We previously investigated SNPs within miRNAs, within miRNA target genes, and within genes participating in miRNA biogenesis for associations with altered risk of developing colon cancer and we determined that few of these SNPs impacted colon cancer risk (Mullany et al., 2015) . However, others have shown that SNPs within miRNAs, while not altering risk of developing cancer, are associated with prognosis (Ryan et al., 2012) . In this paper, we investigate whether SNPs previously investigated with colon cancer risk have any impact survival after diagnosis with colon cancer. We hypothesize that these SNPs will be associated with CRC survival, even if they have not been previously associated with cancer risk.
MATERIALS AND METHODS

Study Population
The study population consisted of individuals previously enrolled in a study of Diet, Activity, and Lifestyle Study of colon cancer (Slattery et al., 1997) for whom Genome Wide Association Study (GWAS) data were available (Table 1) . Study subjects included incident cases of colon cancer between the ages of 30 and 79 who were able to provide a signed informed consent prior to participation in the study. GWAS analysis included only non-Hispanic white individuals. AJCC tumor stage was centrally coded for cancers identified through local tumor registries. The study was approved by the University of Utah Institutional Review Board for Human Subjects; the committee numbers for this paper are IRB_00055877 and IRB_00002335.
GWAS Genotyping
GWAS data were obtained using Illumina HumanHap 550K, 610K as part of the GECCO study and has been described previously (Dunlop et al., 2012) . Imputation to HapMap2 Release 24 was performed using MACH, which was imputed to HapMap Release 22 using BEAGLE. All SNP coordinates were defined using hg19/GRCh37. We excluded SNPs from consideration that failed Illumina quality measures or standard quality control procedures (Laurie et al., 2010) . We further excluded SNPs that showed limited variability in our data (see statistical methods below).
Selection of SNPs
SNPs were previously identified from the literature as being associated with cancer risk and being either within a miRNA gene, a miRNA target gene, or a gene participating in miRNA biogenesis. UCSC (Karolchik et al., 2004) Table Browser was utilized to obtain all SNP coordinates; all coordinates are from the GRCh37 assembly. More detail on how these SNPs were obtained is available in our previous works (Mullany et al., 2015 (Mullany et al., 2016 .
RNA Processing, RNA-Seq Library Preparation and Sequencing and Data Processing
MRNA expression data were analyzed from 197 carcinoma and normal mucosa pairs. Total RNA was extracted from formalin-fixed paraffin embedded tissues and processed as previously described (Slattery et al., 2015a) . Sequencing library construction was done with the Illumina TruSeq Stranded Total RNA Sample Preparation Kit with Ribo-Zero. The samples were then fragmented and primed for complementary DNA (cDNA) synthesis, adapters were then ligated onto the cDNA, and the resulting samples were then amplified using polymerase chain reaction (PCR); the amplified library was then purified using Agencount AMPure XP beads. A more detailed description of the methods can be found in our previous work (Slattery et al., 2015b) . Of these, 175 passed QC based on acceptable number of sequence reads for both carcinoma tissue and normal mucosa. Of these, 71 subjects also had GWAS data available for comparison with mRNA expression data in Python and a pysam library were used to calculate counts for each exon and UTR of the genes using a list of gene coordinates obtained from http://genome.ucsc.edu. We dropped features that were not expressed in our data or for which the expression was missing for the majority of samples. A more detailed description of the methods can be found in our previous work (Slattery et al., 2015b) .
Statistical Analysis
There were 448 unique SNPs from the 871 miRNA-SNP candidate pairs obtained from literature search for SNPs within miRNAs and miRNA target genes. After eliminating miRNAs whose nomenclature did not match those of miRNAs on our platform, there are 642 miRNA-SNP candidate pairs and 363 unique SNPs. An additional 218 SNPs were identified from the literature as residing in miRNA biogenesis genes, yielding a total of 581 SNPs selected for further assessment. Of those 581 SNPs selected, 565 were available in the GWAS dataset.
The GWAS dataset consisted of 2,288 subjects (1,115 cases and 1,173 controls). There are 837 cases with survival data along with other adjustment variables such as AJCC stage and MSI status. We used a Cox proportional hazards model, implemented in SAS, to evaluate the SNPs associations with CRC survival adjusting for age at diagnosis, study center, AJCC stage, and gender and MSI status. CRC-specific survival was calculated from the date of diagnosis until death or the date of the last follow-up. An additive model was used for all SNPs except when the homozygote rare genotype had fewer than six people, at which point a dominant model was used. In some instances, where the recessive model appeared to be more appropriate we re-ran the analysis using the recessive model. We adjusted for multiple comparisons using the step-down Bonferroni correction (Holm) based on the effective number of independent SNPs per chromosomes, using spectral decomposition to determine the number of comparisons within each chromosome, as proposed by Nyholt (2004) and modified by Li and Ji (2005) .
For those SNPs that were significantly associated with survival prior to correction for multiple comparisons, we performed logistic regression analysis adjusting for age at diagnosis/selection, study center and gender to determine if there was any relationship between the significant targeted SNPs and colon cancer risk.
Twenty-nine of the 30 significant (P raw < 0.05 for survival) SNPs had their respective gene in RNA-seq data. We used linear regression to determine if there was a trend in the mean value of the mRNA across the SNP levels adjusting for age, study center and gender. MRNA expression data were analyzed using the log2 of the Reads per Kilobase per Million (RPKMs). We performed 10,000 bootstrap (Davison and Hinkley, 1997) resamplings ('boot' package in R) of the residual of the null model to calculate a distribution of the F statistic and calculate the P value. We looked at mean mRNA expression data for colonic carcinoma, normal colonic mucosa, and the difference between carcinoma and normal colonic mucosa for the mRNA-SNP comparison.
RESULTS
The study included 1,173 controls and 1,115 cases, and approximately 55% of the population were male and 45% were female; the average age at diagnosis/selection was approximately 65 years for both cases and controls (Table 1 ). The average follow-up months were 60.3.
Thirty SNPs were associated significantly with survival prior to adjustment for multiple comparisons and of these, seven SNPs in five genes (ADAMTS1, ADAR, DROSHA, LIN28A, and PRKRA) remained significant after multiple comparison adjustment (Table 2 ). Six of these SNPs (rs2335230 in ADAR, rs10068052, rs13183642, and rs17408227 in DROSHA, rs6598964 in LIN28A, and rs2059691 in PRKRA) increased risk of dying from CRC, while rs12140 (ADAMTS1) decreased risk of dying from CRC [HRR 5 0.44, 95% CI (0.24, 0.83) P Holm 5 0.011].
Of the 30 SNPs associated with survival prior to adjustment, four SNPs in three genes (BRCA1, GDE1, and LIN28A) were associated significantly with risk of developing colon cancer (Table 2) . Of these, only rs6598964 (LIN28A) was significantly associated with survival after adjustment for multiple comparisons. 
SINGLE NUCLEOTIDE POLYMORPHISMS WITHIN MICRORNAS
however it increased risk of dying from CRC [HRR 5 2.26 95% CI (1.52, 3.36; P Holm 5 0.003]. Two SNPs in BRCA1, rs799917 and rs8176318, increased risk of developing colon cancer, while rs2521795 (GDE1) decreased risk of developing colon cancer.
Further evaluation of the 30 SNPs associated with CRC survival prior to adjustment for multiple comparisons showed that five of these SNPs were associated significantly with differential mRNA expression across genotypes (Table 3) . One of these SNPs was associated with mRNA expression in colonic carcinoma tissue (ASB6 rs1045647), two with normal colonic mucosa (FADS2 rs174568 and SF3A3 rs17465826), one with both carcinoma and normal colonic tissues (PRKRA rs2059691), and one with normal colonic mucosa and differential tissue expression (HLA-DPB1 rs1042544). Of these five SNPs only one, (PRKRA rs2059691), was associated significantly with altered risk of dying from CRC after adjustment for multiple comparisons. This SNP, within protein kinase, interferon-inducible double stranded RNA dependent activator (PRKRA) was not associated with risk of developing colon cancer.
DISCUSSION
The hypothesis that a SNP may not influence risk while still influencing survival is not without biological support. Lopez-Camarillo et al. (2012) wrote that certain genes, those participating in biological processes such as apoptosis resistance, migration, invasion, and angiogenesis induction, are more likely to cause metastasis than others; although these processes enable tumors to metastasize, they are not necessarily deleterious under normal cellular circumstances. We observed that, of the 565 SNPs analyzed, seven SNPs remained associated significantly with survival after adjustment for multiple comparisons (P holm < 0.05) and four were associated significantly with risk of developing colon cancer. Only one SNP was associated significantly with survival after adjustment for multiple comparisons as well as with risk: rs6598964 (LIN28A), which decreased risk of developing colon cancer and increased risk of dying from CRC. Five SNPs were associated with mRNA expression in colonic carcinoma tissue, normal colonic mucosa, or differential between carcinoma tissue and normal mucosa; only one of these SNPs, rs2059691 (PRKRA), was also significantly associated survival (P holm 5 0.042 for survival).
Others also have found that SNPs in miRNAs, although not associated with risk, do influence survival. A study by Ryan et al. (2012) identified rs4919510, within hsa-miR-608, was not associated with risk of developing cancer but was associated with increased risk of dying from CRC in a Caucasian population. We analyzed this SNP with CRC survival in our population and found that it was not associated significantly with (P raw 5 0.20) when using a recessive model such as the one used by Ryan et al. (2012) . We do report, however, that rs12140 (ADAMTS1), rs2335230 (ADAR), rs10068052 (DROSHA), rs13183642 (DROSHA), rs17408227 (DROSHA), and rs2059691 (PRKRA) had no impact on risk of developing colon cancer but did influence survival. Additionally, rs6598964 (LIN28A) decreased risk of developing colon cancer but worsened survival.
We previously looked at SNPs within miRNAs, miRNA target genes, and genes participating in miRNA biogenesis. In our previous work we observed an association between rs8176318 (BRCA1) and colon cancer risk, OR AA 1.34 95% CI 1.01, 1.78 (Mullany et al., 2015) , and with rs2059691 (PRKRA) and increased mRNA expression in normal colonic mucosa (Mullany et al., 2016) . We report here that PRKRA rs2059691 is also associated with survival, and that PRKRA mRNA expression increases with the variant allele (G < A) in colonic carcinoma and normal colonic mucosa. We also report here that rs8176318 (BRCA1) increases risk of developing colon cancer OR AA 1.34 95% CI 1.01, 1.78, but does not affect survival.
Rs12140 (ADAMTS1) was included in this analysis because this gene was identified as a target for hsa-miR-140-3p in our previous work (Mullany et al., 2015) . This SNP was not associated with risk of developing colon cancer but did reduce the risk of dying of CRC. The protein encoded by this gene has anti-angiogenic activity, may be involved in inflammatory processes, and is likely necessary for normal growth (O'Leary et al., 2016) . While ADAMTS1 was not differentially expressed by genotype, which implies that this SNP does not impact transcription of ADAMTS1, it is possible that rs12140, which is located in the 3 0 UTR of ADAMTS1, affects the binding of miRNA to this mRNA transcript and thereby reduces repression of this gene. As ADAMTS1 has antiangiogenic properties, it is possible that this gene would not impact colon cancer risk in a normal-functioning cell, however, once a tumor has formed it would reduce the tumor's ability to metastasize. Previously, we saw that hsa-miR-140-3p expression was reduced with the recessive genotype; as miRNA expression has been tied to the presence of its target (Sun et al., 2009; Kai and Pasquinelli, 2010) , it is possible that this SNP causes ADAMTS1 to not be targeted by hsa-miR-140-3p and therefore its anti-angiogenic effect is not diminished, improving a patient's chance of survival.
Only one SNP, rs6598964 (LIN28A), was associated with both risk of developing colon cancer and CRC survival. This SNP decreased risk of developing cancer but increased risk of dying from CRC. This SNP is an intronic variant, and we found no significant changes in expression of LIN28A in normal, carcinoma, or differential tissue, suggesting that this SNP does not impact transcription of this gene. This gene plays a role in miRNA biogenesis, recruiting ZCCHC11 to the miRNA for uridylation, inhibiting the processing of miRNAs, including the tumor suppressor let-7, by Dicer (Heo et al., 2009; Krol et al., 2010; Stefani et al., 2015) . In other studies, overexpression of LIN28 has been shown to contribute to tumorigenesis, by promoting angiogenesis and cell death resistance and increasing cell proliferation (Wang et al., 2015) , and be associated with advanced malignancies (Hamano et al., 2012) . It is intuitive that a gene regulating metastasis would negatively impact survival while not necessarily be detrimental under normal circumstances, thus not influencing risk. It is, however, somewhat perplexing that a SNP in a metastatic regulating gene would decrease risk of cancer while being detrimental to survival. In order to determine whether an outside factor was confounding our results, we re-ran the risk analysis adjusting for factors previously shown to influence risk of CRC, including age, sex, center, recent aspirin/NSAID use, smoking status (current, former, or never), body mass index, and lifetime physical activity; this adjustment did not change the results. Zhang et al. (2014) report that rs221636, a SNP within the 3 0 UTR of LIN28B, a homolog of LIN28A, was associated with altered risk of oral cancer in a Chinese Han population, with decreased risk in subjects who did not drink with AT or TT genotypes compared to drinkers with the AA genotype. Zhang et al. (2014) suggested this finding was the result of a "synergistic effect" between drinking and the variant in LIN28B. We looked at long-term and current use of alcohol with rs6598964 and found that at lower levels of risk for moderate drinkers [GG/GA: OR 0.99 95% CI (0.80, 1.22 CI (0.76, 2.17) ]. This suggests there may be a possible interaction between alcohol use and rs6598964 in regard to the development of colon cancer, although it was not statistically significant in our data. Lin28A and Lin28B transgenic animals have been shown to be more sensitive to insulin and have lower peripheral glucose levels (Thornton and Gregory, 2012) ; hyperinsulimia and hyperglycemia have been linked to colon cancer development (Giovannucci, 2007) . It is therefore possible that rs6598964 creates a more functional protein that is initially able to reduce glucose levels, potentially reducing risk of colon cancer, however once a tumor is formed, the angiogenic and metastatic properties of Lin28A prevail and we see worsened survival in subjects with the AA genotype.
The only SNP significantly associated with survival and mRNA expression was rs2059691 (PRKRA). This SNP increased risk of death from CRC (OR 1.87 95% CI 1.11, 3.13, P holm 5 0.042) and increased mRNA expression with the homozygous rare genotype in both colonic carcinoma tissue (P value 5 0.024) and normal colonic mucosa (P value < 0.001); mRNA expression was higher in colonic carcinoma tissue than in normal colonic mucosa. PRKRA, as a protein kinase, belongs to a group of genes that are considered metastatic initiation genes (Lopez-Camarillo et al., 2012) . As rs2059691 (PRKRA) increased risk of death from CRC and was not associated with risk of developing colon cancer, it is likely that this SNP affects tumor progression and not initiation.
We used mRNA expression from RNA-Seq data in this analysis; it is possible that the SNPs we investigated in this study may not impact mRNA transcription, but do impact translation of the mRNA into protein or the tertiary structure of the protein product. If this were the case, the normal function of the protein would be altered and could be responsible for the altered risk of CRC or impact on survival; however, we would not detect this effect. Additionally, as we restrict our study sample to those samples for which we had mRNA expression data, it is possible that our reduced sample size limited our ability to detect weaker associations between SNPs and survival. We consider our inclusion of paired mRNA expression data an asset to the investigation and the field, and we encourage larger studies to replicate our findings.
We investigated whether SNPs previously looked at with colon cancer risk impact CRC survival. Few SNPs we analyzed were associated with either risk of colon cancer or survival, and only one was associated with both. The genes that negatively impact CRC survival, but have a positive influence on risk or do not affect risk of colon cancer, appear to have a large role in biological processes that are involved in the metastatic process, even those that predominantly participate in miRNA biogenesis. It is unclear the exact mechanism by which these SNPs influence risk and survival, as many do not appear to affect mRNA transcription; we therefore encourage others to investigate the impact of these SNPs on gene translation and protein function.
